Cypher Select (Cordis)

Cypher Select is an advanced-generation sirolimus-eluting coronary stent (SES) developed by Cordis Corporation (formerly a subsidiary of Johnson & Johnson). It is a drug-device combination product consisting of a stainless steel stent scaffold coated with a non-erodible polymer that facilitates the controlled, local elution of sirolimus (also known as rapamycin). Sirolimus is a macrocyclic lactone that acts as a potent mTOR inhibitor, binding to the FKBP12 protein to form a complex that inhibits the cell cycle progression of smooth muscle cells from the G1 to the S phase. This mechanism effectively suppresses neointimal hyperplasia, thereby reducing the risk of in-stent restenosis following percutaneous coronary intervention. The Cypher stent family was the first drug-eluting stent (DES) to receive FDA approval (2003) and CE marking (2002), and it is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions in native coronary arteries, including complex cases such as bifurcation lesions.

Brand names

Cypher SelectCypher Select Plus

Other names

sirolimus-eluting coronary stentCypher SESCypher stent